| Name | Title | Contact Details |
|---|
Were big on K-12 Student Software Solutions ✨
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Consumer Point of Sale Financing for all. Shop Now. Pay Later. ChargeAfter is an eCommerce consumer financing multi-lender platform for checkout financing.
Synopsys is an American electronic design automation company that focuses on silicon design and verification, silicon intellectual property and software security and quality.